Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04661878
Other study ID # Pro00103309
Secondary ID K01MH118072
Status Completed
Phase N/A
First received
Last updated
Start date June 21, 2022
Est. completion date April 2, 2024

Study information

Verified date April 2024
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall goal of this pilot randomized-controlled trial (RCT) is to pilot MASI (MAsakhane Siphucule Impilo Yethu; Xhosa for "Let's empower each other and improve our health"), an ART adherence-supporting smartphone app with 50 adolescents and young adults living with HIV to assess its feasibility and acceptability and to explore preliminary effects on ART adherence and social support.


Description:

Interventions that engage adolescents and young adults with HIV (AYAHIV) to improve adherence to antiretroviral therapy (ART) are urgently needed. AYAHIV repeatedly demonstrate suboptimal adherence to ART, which is associated with increased morbidity and mortality. Developing adherence-promoting interventions for AYAHIV requires an understanding of factors that shape adherence from multiple levels. Developmental theories suggest that adolescents and young adults are particularly sensitive to their social networks. Mobile health (mHealth) interventions, those that use mobile technology (e.g., smartphones apps) to transmit health information, hold promise as an effective way to improve ART adherence. These smartphone apps can be used to engage social networks and provide social support. Access to mobile phone technology is rapidly increasing among youth in South Africa, making mHealth interventions feasible and potentially scalable in this setting. We developed MASI (MAsakhane Siphucule Impilo Yethu; Xhosa for "Let's empower each other and improve our health"), an ART adherence-supporting smartphone app for AYAHIV in South Africa. MASI was culturally adapted to the South African context using the evidence based HealthMpowerment platform. HealthMpowerment is a smartphone app-based intervention originally developed by Dr. Lisa Hightow-Weidman, and was developed based on the Institute of Medicine's Integrated Behavior Model with extensive input from youth. The app is designed to foster social support, offer tools for self-monitoring and habit formation, provide resources for goal setting and action planning, and present users with engaging informational resources. This pilot randomized-controlled trial (RCT) is funded through a K01 Mentored Research Scientist Development Award. Prior to the pilot RCT, the study team developed and customized MASI through in-depth interviews and beta-testing with adolescents living with HIV in Cape Town. For the pilot RCT, participants will be randomized to either the full version of the MASI app or an information-only version of MASI control condition (1:1, with stratification by gender). Participants will be asked to engage with MASI for 6 months. All participants will complete baseline and follow-up assessments at 3- and 6-months.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date April 2, 2024
Est. primary completion date March 15, 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years to 21 Years
Eligibility Inclusion Criteria: - Age >= 15 years and <= 21 years - Knows HIV status (Screened adolescents who do not know their HIV status will receive information on free voluntary HIV counseling and testing services) - Living with HIV - Has been prescribed medication to treat HIV - Not attending school for learners with special needs (e.g., School of Skills) - Has not repeated a grade in school more than once - Has a smartphone that can download apps - Feels comfortable using an app with content in English - No plan to move outside of Cape Town in the next six months - Has not previously participated in the MASI app testing phase of our study - Able to successfully install the MASI app on their smartphone Exclusion Criteria: - Failure to meet any of the inclusion criteria - Child dissent despite parent, legal guardian, caregiver informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Social Support
The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.
Informational Resources
The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
Self-Monitoring and habit formation
The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.
Goal setting and action planning
The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.

Locations

Country Name City State
South Africa University of Cape Town Cape Town

Sponsors (5)

Lead Sponsor Collaborator
Duke University Florida State University, National Institute of Mental Health (NIMH), University of Cape Town, University of North Carolina

Country where clinical trial is conducted

South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intervention feasibility: Number of days participants log in to the app as recorded by app backend paradata Feasibility will be measured by the number days participants log in to the app as recorded by app backend paradata 3 months, 6 months
Primary Intervention feasibility: Total time participants spend using the app Feasibility will be measured by the total time, in minutes, participants spend using app as recorded by app backend paradata. 3 months, 6 months
Primary Intervention feasibility: Number of days participants log medications using the app as recorded by app backend paradata Feasibility will be measured by the number of days participants log medications in the app as recorded by app backend paradata. 3 months, 6 months
Primary Intervention acceptability: Composite score from adapted system usability scale Acceptability will be measured by an average of participants' scores on an adapted version of the System Usability Scale (SUS), a scale giving a global view of subjective assessments of usability. Total possible range: 0 - 100. Higher score indicates higher usability and helpfulness (better outcome). Average SUS >68 (average for digital health apps) will be considered acceptable. 3 months, 6 months
Secondary Adherence to ART, as measured by 30-day recall of missed doses Adherence to antiretroviral therapy will be measured using the participant's self-reported number of missed ART doses in the past 30 days. 3 months
Secondary Adherence to ART, as measured by 30-day recall of missed doses Adherence to antiretroviral therapy will be measured using the participant's self-reported number of missed ART doses in the past 30 days. 6 months
Secondary Perceived social support and social isolation using adapted Medical Outcomes Study Social Support Survey (MOS-SS) Perceived social social support will be measured using an adapted version of the Medical Outcomes Study Social Support Survey (MOS-SS), which measures four domains of social support: emotional/informational support, tangible support, affectionate support, and positive social interaction. Total possible range: 12 - 48. Higher score indicates higher social support (better outcome). 3 months
Secondary Perceived social support and social isolation using adapted Medical Outcomes Study Social Support Survey (MOS-SS) Perceived social social support will be measured using an adapted version of the Medical Outcomes Study Social Support Survey (MOS-SS), which measures four domains of social support: emotional/informational support, tangible support, affectionate support, and positive social interaction. Total possible range: 12 - 48. Higher score indicates higher social support (better outcome). 6 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2